Thus, it is not surprising that for EZH2—central in maintaining PRC2 activity—tumor suppressor function has been proposed when in 2010, inactivating point mutations in myeloid neoplasms were discovered by different groups [6–8]. Here, EZH2 is linked to neoplasm.